(NYSE: CRL) Charles River Laboratories International's forecast annual revenue growth rate of 2.13% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.68%.
Charles River Laboratories International's revenue in 2025 is $4,023,704,000.On average, 19 Wall Street analysts forecast CRL's revenue for 2025 to be $199,224,226,608, with the lowest CRL revenue forecast at $190,070,149,002, and the highest CRL revenue forecast at $208,378,304,214. On average, 19 Wall Street analysts forecast CRL's revenue for 2026 to be $202,570,878,636, with the lowest CRL revenue forecast at $194,450,325,921, and the highest CRL revenue forecast at $214,727,099,973.
In 2027, CRL is forecast to generate $212,069,464,539 in revenue, with the lowest revenue forecast at $199,962,458,673 and the highest revenue forecast at $235,692,890,619.